About Matchpoint Therapeutics
Matchpoint Therapeutics is a company based in Cambridge (United States) founded in 2021 by Tinghu Zhang, Jianwei Che, Edward Chouchani, and Nathanael Gray. Matchpoint Therapeutics has raised $100 million across 2 funding rounds from investors including ARE, Atlas Venture and Access Industries. The company has 27 employees as of December 31, 2022. Matchpoint Therapeutics offers products and services including Covalent Medicines, Chemoproteomics Platform, and Covalent Library. Matchpoint Therapeutics operates in a competitive market with competitors including Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and Dotmatics, among others.
- Headquarter Cambridge, United States
- Employees 27 as on 31 Dec, 2022
- Founders Tinghu Zhang, Jianwei Che, Edward Chouchani, Nathanael Gray
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$100 M (USD)
in 2 rounds
-
Latest Funding Round
$70 M (USD), Series A
Oct 14, 2022
-
Investors
ARE
& 5 more
-
Employee Count
27
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Matchpoint Therapeutics
Matchpoint Therapeutics offers a comprehensive portfolio of products and services, including Covalent Medicines, Chemoproteomics Platform, and Covalent Library.
Small molecules targeting proteins in immune diseases for treatment.
Tool for detecting binding pockets in proteins for drug discovery.
Collection of compounds for advancing covalent drug candidates.
People of Matchpoint Therapeutics
Unlock access to complete
Funding Insights of Matchpoint Therapeutics
Matchpoint Therapeutics has successfully raised a total of $100M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $70 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $70.0M
-
First Round
First Round
(01 Nov 2021)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2022 | Amount | Series A - Matchpoint Therapeutics | Valuation | Sanofi Ventures | |
| Nov, 2021 | Amount | Seed - Matchpoint Therapeutics | Valuation | Atlas Venture , Access Industries |
|
Investors in Matchpoint Therapeutics
Matchpoint Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Atlas Venture and Access Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Investment and holding company controlled by Len Blavatnik
|
Founded Year | Domain | Location | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by Matchpoint Therapeutics
Financial Statements - Matchpoint Therapeutics
Matchpoint Therapeutics Comparisons
Competitors of Matchpoint Therapeutics
Matchpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and Dotmatics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery and development services for small molecules are provided.
|
|
| domain | founded_year | HQ Location |
CDMO services for pharma, biotech, and specialty ingredients are provided.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| domain | founded_year | HQ Location |
Generic drugs and clinical research services are provided globally.
|
|
| domain | founded_year | HQ Location |
AI powered scientific data management and workflow automation solutions
|
|
| domain | founded_year | HQ Location |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
Latest news on Matchpoint Therapeutics
Frequently Asked Questions about Matchpoint Therapeutics
Matchpoint Therapeutics was founded in 2021.
Matchpoint Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Andre Turenne is the current CEO of Matchpoint Therapeutics.
Matchpoint Therapeutics is a funded company, having raised a total of $100M across 2 funding rounds to date. The company's 1st funding round was a Seed of $30M, raised on Nov 01, 2021.
As of Dec 31, 2022, the latest employee count at Matchpoint Therapeutics is 27.
Matchpoint Therapeutics was established in 2021 in Cambridge, United States, within the biotechnology sector. Small molecule medicines are developed, and analytics services are offered to support therapeutic advancements. The company operates from its base in the U.S., focusing on precision medicine solutions. Co-founders Tinghu Zhang, Jianwei Che, Edward Chouchani, and Nathanael Gray lead the scientific efforts, while Andre Turenne serves as CEO. Core activities emphasize data-driven drug discovery processes.
Matchpoint Therapeutics offers Covalent Medicines, Chemoproteomics Platform, and Covalent Library.
Matchpoint Therapeutics has 6 investors. Key investors include ARE, Atlas Venture, Access Industries, Sanofi Ventures, and Vertex Ventures HC.